PTO/SB/08A (08-03)

Approved for use through 07/31/2006 OMB 0651-003 U.S. Patent and Trademark Other; U.S. DEPARTMENT OF COMMUNICATION OF A COMMUNICATION OF THE PARTMENT OF COMMUNICATION OF THE PARTMENT OF THE PARTMENT OF THE PARTMENT OF T ough 07/31/2006 OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)						ication Number	10/517,869	10/517.869		
						g Date	October 12, 2005 Anders Lehmann			
						Named Inventor				
						Init	614			
(Use as many sneets as necessary)					Exan	niner Name	pivack, Phyllis G.			
Sheet	1 of 1		1			1103326-0946				
			U.S.	PATENT	DOCU	MENTS				
Examiner Initials*	Cite No.1	Document Number		Publicati		Name of Patente	e Pages, Columns	Pages, Columns, Lines, Where Relevant		
	No.			MM-DD	-YYYY	Applicant of Cite				
		Number-Kind Code ^{2 (f/known)}				Document		Passages/Figures Appear		
	+-	1								
		1								
			FOREI	GN PATE	NT DO	CUMENTS				
Examiner Initials*	Cite	Foreign Patent Document		Public	ation Date	Name of Patentee	or Pages, Columns,			
	No.1			MM-D	D-YYYY	Applicant of Cite				
						Document	Relevant Passages	.		
						Document	Or Relevant Figur			
		Country Code	3-Number4-Kind Code5(rf los	man)			Appear	C3		
		Country Coun	Trumber Tema Code (y an				rippeur			
	+-	+		_						
			NON PATE	NT LITER	ATURI	E DOCUMENTS				

Include name of the author (in CAPITAL LETTERS), title of the article (when Cite Examiner appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), Т Initiale No. date, page(s), volume-issue number(s), publisher, city and/or country where published. Patentee AstraZeneca's response, dated 25 June 2009, to the Opposition against EP 1 513 525 B1 filed by Addex Pharma S.A. and separately by Novartis AG. The EPO's preliminary and non-binding opinion dated 19 October 2009 with regard to the Opposition against EP 1 513 525 B1. Supplemental submission, dated 28 July 2010, by the opponent Novartis AG in its Opposition against EP 1 513 525 B1. Trilateral Project B3b: Mutual understanding in search and examination: Report on comparative study on biotechnology patent practices: Theme - comparative study on "reach-through claims", EPO, JPO, USPTO, November 5-9, 2001. Examiner Signature Date Considered

"EXAMPS, fall if influence consistent, where or at claims in a conference or all NET URD. The fall made placing drives of a sin conference and extracted by the fall of the fa EXAMINER. Initial if reference considered, whether or not citation is in conformance wife unique citation designation number (optional). See Kinds Codes of USPTO Patent Decum